Clinical Trials · NCT06178146

Thymosin Alpha-1 for irAE Secondary to ICIs

Name: Thymosin Alpha-1 for irAE Secondary to ICIs
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

UnknownPhase 4Thymosin Alpha-1

Phase: Phase 4
Recruitment status: Unknown
Sponsor: Jun Wang
Enrollment: 40
Start date: Sep 2023
Locations: 1 site, China
Primary endpoint: Symptoms relieving rate

View Thymosin-Alpha-1 compound reference